You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

48 search results for: disease control

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

20 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

The Impact of Advanced Systemic Therapies on <b>Disease</b> <b>Control</b> and Potential Remission in Atopic Dermatitis

expert video

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

10 min

Dermatology

Exploring the concept of disease modification relating to therapeutic interventions with targeted systemic therapies in atopic dermatitis.

IRS-ISIAN 2024 | Guideline Definitions of <b>Control</b> in CRSwNP

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

Impact of Advanced Systemic Therapies on <b>Disease</b> <b>Control</b> in AD

expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

Dermatology

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

Infographic

Importance of Monitoring and Maintenance in EoE

5 min

Gastroenterology

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL

Most Children With Atopic Dermatitis Have Un<b>control</b>led <b>Disease</b>

expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

1 min

Dermatology

Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.

What do we mean by <b>disease</b> <b>control</b> in AD?

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

On-Treatment Asthma Remission: Moving Beyond <b>Control</b>

interactivity

On-Treatment Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma

expert video

Guideline and Patient Management in CSU

4 min

Dermatology

Drs. Maurer and Ensina discuss cutting-edge strategies for managing CSU in this insightful interview.

expert video

Treatment Goals, Current and Emerging Therapies in CSU

6 min

Dermatology

Drs. Maurer and Ensina delve into their thoughts on the latest treatment goals and emerging therapies for CSU in this illuminating interview.

What proportion of patients can achieve <b>control</b> in CRSwNP?

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis

expert video

New Perspectives on Disease Modification in Atopic Dermatitis

48 min

Dermatology

An exploration into the concept and potential of disease modification through therapeutic interventions in AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Dominican RepublicChange country/region